What is Opus Genetics, Inc.'s earnings per share (EPS)?

Opus Genetics, Inc. (IRD) reported diluted earnings per share of -$0.80 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opus Genetics, Inc. (IRD) Financials

IRD

Trailing 12 months to June 30, 2026

Revenue $9.9M -36.1% YoY

Net Income -$107.6M -84.7% YoY

EPS (Diluted) -$1.35 YoY not available

Operating Cash Flow -$40.7M -27.8% YoY

Market Cap $381.0M as of Oct 3, 2026

Price / Sales 38.7x on $9.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IRD SEC filings page.

Opus Genetics, Inc. (IRD) reported $9.9M in revenue over the twelve months to Jun 30, 2026, down 36.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IRD FY2025 2026-10-03

Opus Genetics operates as a development-stage business: research spending exceeds revenue, while financing supplies cash that operations consume.

In FY2025, research and development reached $30.8M against revenue of $14.2M, so the reported economics still reflect investment ahead of commercial scale. Operating cash flow of -$35.3M was less negative than the net loss of $49.6M, indicating that accounting expenses and cash spending did not move together completely.

The business became more cash-intensive: operating cash flow moved from -$25.6M in FY2024 to -$35.3M in FY2025, while R&D also increased. That combination suggests higher development spending, rather than revenue growth, remains the main operating requirement.

External financing is central to the balance sheet. FY2025 financing cash flow of $50.0M exceeded operating cash use, while shares outstanding rose to 71.1M from 45.5M; the company is funding activity primarily through capital raised rather than internally generated cash. Reported liquidity equaled 15.3 months of the latest annual operating outflow, a balance-to-outflow comparison rather than a forecast.

Financial Health Signals

Financial Health Score 38/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Opus Genetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Opus Genetics, Inc. held $45.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $35.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Opus Genetics, Inc. scores 39/100 among other emerging companies.

Dilution

Opus Genetics, Inc. had 71M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Opus Genetics, Inc. scores 15/100 among other emerging companies.

R&D Intensity

Opus Genetics, Inc. spent $30.8M on research and development in fiscal year 2025, which was 58.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Opus Genetics, Inc. scores 81/100 among other emerging companies.

Revenue Progress

Opus Genetics, Inc. reported revenue of $14.2M in fiscal year 2025, against $11.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Opus Genetics, Inc. scores 25/100 among other emerging companies.

Burn Trend

Opus Genetics, Inc.'s operations used $35.3M of cash in fiscal year 2025, against $25.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Opus Genetics, Inc. scores 1/100 among other emerging companies.

Balance Sheet

Opus Genetics, Inc.'s cash, cash equivalents and investments came to $45.1M at the end of fiscal year 2025, against $34.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Opus Genetics, Inc. scores 65/100 among other emerging companies.

Altman Z-Score Distress

0.05

Opus Genetics, Inc. scores 0.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($381.0M) relative to total liabilities ($34.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Opus Genetics, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Opus Genetics, Inc. reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Opus Genetics, Inc. reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$755K

YoY-73.8%

QoQ-65.0%

Opus Genetics, Inc. generated $755K in revenue in Q2 2026. This represents a decrease of 73.8% from the same quarter a year earlier. Against the prior quarter it is down 65.0%.

EBITDA

-$16.5M

YoY-85.2%

QoQ-14.7%

Opus Genetics, Inc.'s EBITDA was -$16.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 85.2% from the same quarter a year earlier. Against the prior quarter it is down 14.7%.

Net Income

-$8.1M

YoY-9.1%

QoQ+87.6%

Opus Genetics, Inc. reported -$8.1M in net income in Q2 2026. This represents a decrease of 9.1% from the same quarter a year earlier. Against the prior quarter it is up 87.6%.

EPS (Diluted)

-$0.14

YoY-16.7%

Opus Genetics, Inc. earned -$0.14 per diluted share (EPS) in Q2 2026. This represents a decrease of 16.7% from the same quarter a year earlier.

Cash & Balance Sheet

Cash & Debt

$88.8M

YoY+173.9%

QoQ+48.1%

5Y CAGR+29.7%

10Y CAGR+27.4%

Opus Genetics, Inc. held $88.8M in cash against $35.3M in long-term debt as of Q2 2026.

Shares Outstanding

83M

YoY+38.9%

5Y CAGR+37.5%

10Y CAGR-9.0%

Opus Genetics, Inc. had 83M shares outstanding in Q2 2026. This represents an increase of 38.9% from the same quarter a year earlier.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$11.2M

YoY+86.1%

QoQ+6.0%

Opus Genetics, Inc. invested $11.2M in research and development in Q2 2026. This represents an increase of 86.1% from the same quarter a year earlier. Against the prior quarter it is up 6.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

IRD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$9.9M	$14.2M+29.1%	$11.0M-42.3%	$19.0M-52.2%	$39.9M+6665.7%	$589K	$0-100.0%	$3.0M	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
R&D Expenses	$38.6M	$30.8M+14.8%	$26.9M+52.1%	$17.7M+23.0%	$14.4M-5.4%	$15.2M+128.2%	$6.6M+21.4%	$5.5M-58.2%	$13.1M+22.3%	$10.7M+6.2%	$10.1M-16.9%	$12.1M+73.2%	$7.0M+115.7%	$3.3M-4.1%	$3.4M-71.7%	$12.0M
SG&A Expenses	$21.8M	$22.0M+20.7%	$18.2M+52.3%	$12.0M+64.5%	$7.3M-10.5%	$8.1M+188.2%	$2.8M+54.8%	$1.8M-75.5%	$7.4M+11.9%	$6.6M+5.0%	$6.3M+3.4%	$6.1M-2.2%	$6.3M+32.3%	$4.7M+74.2%	$2.7M-23.5%	$3.5M
Operating Income	-$50.6M	-$38.6M+37.8%	-$62.1M-487.7%	-$10.6M-158.0%	$18.2M+180.3%	-$22.7M-13.7%	-$20.0M-376.2%	-$4.2M+79.6%	-$20.5M-18.3%	-$17.4M-5.7%	-$16.4M+10.1%	-$18.3M-37.6%	-$13.3M-66.3%	-$8.0M-21.3%	-$6.6M+59.2%	-$16.1M
EBITDA	N/A	-$38.5M+37.9%	-$62.1M-487.9%	-$10.6M-157.9%	$18.2M+180.3%	-$22.7M-13.7%	-$20.0M-380.7%	-$4.2M+79.7%	-$20.5M-18.4%	-$17.3M-5.7%	-$16.4M+10.2%	-$18.2M-37.7%	-$13.2M-66.7%	-$7.9M-21.5%	-$6.5M+59.4%	-$16.1M
Interest Expense	N/A	$129K	$0	$0-100.0%	$9K+350.0%	$2K-100.0%	$6.8M+385.9%	$1.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0-100.0%	$12K-96.2%	$315K	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	-$107.6M	-$49.6M+13.8%	-$57.5M-476.1%	-$10.0M-155.8%	$17.9M+131.6%	-$56.7M-130.3%	-$24.6M-299.1%	-$6.2M+57.1%	-$14.4M+43.2%	-$25.3M-171.8%	-$9.3M+35.3%	-$14.4M+22.3%	-$18.5M-95.0%	-$9.5M-52.6%	-$6.2M+45.1%	-$11.3M
EPS (Basic)	N/A	-$0.80+62.8%	-$2.15-367.4%	-$0.46-151.1%	$0.90+123.6%	-$3.82+27.7%	-$5.28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.35	-$0.80	-$2.15	-$0.46-152.9%	$0.87+122.8%	-$3.82	-$5.28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	62M	27M	22M+4.8%	21M+38.7%	15M	5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$755K-73.8%	$2.2M-50.6%	$3.9M-10.2%	$3.1M-20.4%	$2.9M+159.2%	$4.4M+155.4%	$4.3M+154.4%	$3.9M-67.6%
R&D Expenses	$11.2M+86.1%	$10.6M+33.0%	$10.4M+48.3%	$6.4M-28.6%	$6.0M-1.1%	$8.0M+67.5%	$7.0M+83.1%	$9.0M+157.1%
SG&A Expenses	$6.0M+4.5%	$5.9M-6.3%	$4.9M-33.0%	$5.0M+72.1%	$5.8M+71.9%	$6.3M+35.9%	$7.3M+122.5%	$2.9M+40.8%
Operating Income	-$16.5M-85.0%	-$14.4M-44.7%	-$11.5M+69.9%	-$8.3M-3.8%	-$8.9M-6.9%	-$9.9M-28.8%	-$38.0M-600.5%	-$8.0M-225.4%
EBITDA	-$16.5M-85.2%	-$14.4M-44.7%	-$11.4M+69.9%	-$8.3M-3.6%	-$8.9M-6.8%	-$9.9M-28.6%	-$38.0M-600.7%	-$8.0M-225.4%
Interest Expense	N/A	$69K	N/A	$68K	N/A	$0	N/A	$0
Income Tax	$0	$0	$0	$0	$0	$0	$0+100.0%	$0-100.0%
Net Income	-$8.1M-9.1%	-$65.5M-699.8%	-$16.5M+53.0%	-$17.5M-131.9%	-$7.4M+4.4%	-$8.2M-15.3%	-$35.1M-632.7%	-$7.5M-235.3%
EPS (Basic)	-$0.08+33.3%	-$0.75-212.5%	-$0.21+83.5%	-$0.25+13.8%	-$0.12+60.0%	-$0.24+17.2%	-$1.27-504.8%	-$0.29-211.5%
EPS (Diluted)	-$0.14-16.7%	-$0.75	-$0.21	-$0.25	-$0.12	-$0.24	-$1.27	-$0.29-216.0%
Diluted Shares (Avg)	111M+75.8%	87M	N/A	71M	63M	34M	N/A	26M+16.7%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

IRD Balance Sheet

IRD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$50.2M+36.3%	$36.9M-31.7%	$53.9M+10.1%	$49.0M+87.9%	$26.1M+47.5%	$17.7M+891.1%	$1.8M-88.9%	$16.0M-43.3%	$28.3M+34.4%	$21.0M-15.2%	$24.8M-26.0%	$33.5M+71.5%	$19.6M+31.1%	$14.9M+9.0%	$13.7M
Current Assets	$50.0M+36.7%	$36.6M-32.1%	$53.9M+10.1%	$49.0M+87.9%	$26.1M+47.5%	$17.7M+902.7%	$1.8M-88.9%	$15.9M-43.5%	$28.1M+34.5%	$20.9M-15.2%	$24.7M-26.2%	$33.4M+73.3%	$19.3M+40.1%	$13.8M+13.3%	$12.2M
Cash & Equivalents	$45.1M+48.7%	$30.3M-40.0%	$50.5M+18.5%	$42.6M+73.8%	$24.5M+49.6%	$16.4M+966.9%	$1.5M-82.4%	$8.7M-1.7%	$8.9M-23.1%	$11.6M+13.5%	$10.2M+3.8%	$9.8M-47.4%	$18.7M+38.6%	$13.5M+36.8%	$9.9M
Short-Term Investments	$0-100.0%	$2K-86.7%	$15K-69.4%	$49K-77.6%	$219K	$0	$0-100.0%	$6.0M-66.6%	$17.9M+105.2%	$8.7M-34.0%	$13.2M-42.1%	$22.9M+22772.1%	$100K0.0%	$100K-94.9%	$1.9M
Accounts Receivable	$2.0M-44.0%	$3.6M+284.8%	$926K-28.7%	$1.3M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$34.9M+15.8%	$30.1M+645.6%	$4.0M+46.8%	$2.8M-28.6%	$3.9M-87.6%	$31.1M+233.4%	$9.3M-47.3%	$17.7M+54.0%	$11.5M+189.1%	$4.0M-33.9%	$6.0M-13.3%	$7.0M+0.3%	$6.9M+28.7%	$5.4M+80.5%	$3.0M
Current Liabilities	$7.8M-31.1%	$11.3M+179.4%	$4.0M+46.8%	$2.8M-28.6%	$3.9M+21.0%	$3.2M-65.9%	$9.3M+196.4%	$3.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Non-Current Liabilities	$27.1M+43.9%	$18.8M	$0	$0	$0-100.0%	$28.0M	$0-100.0%	$14.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$1.1M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.3M+128.3%	$6.7M-86.5%	$49.9M+7.9%	$46.2M+108.1%	$22.2M+265.0%	-$13.5M-78.1%	-$7.6M-345.0%	-$1.7M-110.1%	$16.8M-1.7%	$17.1M-9.1%	$18.8M-29.4%	$26.6M+110.5%	$12.6M+32.4%	$9.5M-10.9%	$10.7M
Retained Earnings	-$188.6M-35.7%	-$139.0M-70.6%	-$81.5M-14.0%	-$71.5M+20.0%	-$89.4M-173.5%	-$32.7M-305.6%	-$8.1M+94.8%	-$154.7M-10.2%	-$140.3M-22.0%	-$115.0M-8.8%	-$105.7M-15.7%	-$91.3M-25.4%	-$72.8M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$93.0M+140.4%	$66.8M+38.7%	$50.2M+36.3%	$36.1M-10.6%	$38.7M-13.8%	$48.2M-7.1%	$36.9M-31.7%	$40.4M-25.5%
Current Assets	$92.7M+141.2%	$66.6M+39.0%	$50.0M+36.7%	$35.9M-11.1%	$38.4M-14.3%	$47.9M-7.6%	$36.6M-32.1%	$40.4M-25.5%
Cash & Equivalents	$88.8M+173.9%	$60.0M+43.5%	$45.1M+48.7%	$30.8M-15.9%	$32.4M-21.7%	$41.8M-11.4%	$30.3M-40.0%	$36.6M-13.5%
Short-Term Investments	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$1K-80.0%	$2K-86.7%	$3K-72.7%
Accounts Receivable	$1.0M-69.4%	$1.7M-43.8%	$2.0M-44.0%	$2.9M+57.0%	$3.4M+150.3%	$3.1M+60.1%	$3.6M+284.8%	$1.9M-81.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$106.0M+400.0%	$112.6M+161.3%	$34.9M+15.8%	$30.2M+395.2%	$21.2M+404.8%	$43.1M+644.7%	$30.1M+645.6%	$6.1M+55.8%
Current Liabilities	$7.6M-62.3%	$9.3M-61.5%	$7.8M-31.1%	$29.1M+377.7%	$20.2M+381.0%	$24.3M+319.1%	$11.3M+179.4%	$6.1M+55.8%
Non-Current Liabilities	$98.3M+9734.9%	$103.3M+448.1%	$27.1M+43.9%	$1.1M	$1.0M	$18.8M	$18.8M	$0
Long-Term Debt	$35.3M+3428.1%	$1.2M	$1.1M	$1.1M	$1.0M	N/A	$0	N/A
Total Equity	-$13.0M-174.3%	-$45.8M-1003.5%	$15.3M+128.3%	$6.0M-82.6%	$17.5M-57.0%	$5.1M-89.0%	$6.7M-86.5%	$34.3M-31.8%
Retained Earnings	-$262.2M-69.6%	-$254.1M-72.6%	-$188.6M-35.7%	-$172.1M-65.7%	-$154.6M-60.5%	-$147.2M-66.2%	-$139.0M-70.6%	-$103.9M-35.5%

Not reported in any period shown, so not listed: Inventory, Goodwill.

IRD Cash Flow Statement

IRD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$40.7M	-$35.3M-37.8%	-$25.6M-2200.0%	-$1.1M-107.8%	$14.3M+173.9%	-$19.4M-185.0%	-$6.8M-89.2%	-$3.6M+80.9%	-$18.8M-22.2%	-$15.4M-16.6%	-$13.2M+23.8%	-$17.4M-57.2%	-$11.0M-38.3%	-$8.0M-20.6%	-$6.6M+57.4%	-$15.5M
Depreciation & Amortization	N/A	$53K+430.0%	$10K+66.7%	$6K+50.0%	$4K0.0%	$4K-50.0%	$8K-80.5%	$41K-15.0%	$48K+13.8%	$42K+28.7%	$33K+19.7%	$27K-2.9%	$28K-23.7%	$37K-12.4%	$42K-6.0%	$45K
Stock-Based Compensation	N/A	$3.4M+1.1%	$3.4M-4.2%	$3.5M+94.2%	$1.8M-5.6%	$1.9M+27.1%	$1.5M+389.0%	$308K-74.9%	$1.2M+17.6%	$1.0M-25.9%	$1.4M+35.8%	$1.0M+70.4%	$609K+7.7%	$565K+144.8%	$231K-63.8%	$639K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$25K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$6.8M-87.9%	-$3.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0-100.0%	$1.2M	$0	$0+100.0%	-$100K-118.6%	$539K+2256.0%	-$25K-100.2%	$11.9M+227.1%	-$9.4M	N/A	N/A	N/A	$846K-61.4%	$2.2M+501.2%	-$546K
Financing Cash Flow	$97.2M	$50.0M+1095.0%	$4.2M-53.4%	$9.0M+137.2%	$3.8M-86.3%	$27.6M+30.7%	$21.1M+349.0%	$4.7M-30.5%	$6.8M-69.4%	$22.1M	N/A	N/A	N/A	$12.3M+53.2%	$8.1M-40.8%	$13.6M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$11.9M-16.4%	-$12.7M-41.5%	-$9.8M-32.2%	-$6.2M-20.0%	-$10.3M-40.8%	-$9.0M-57.3%	-$7.4M-263.5%	-$5.1M-70.8%
Depreciation & Amortization	$14K0.0%	$13K0.0%	$13K+30.0%	$13K	$14K	$13K	$10K+233.3%	$0-100.0%
Stock-Based Compensation	$1.4M+57.0%	$1.5M+60.4%	N/A	$816K+5.2%	$896K+11.2%	$913K-7.3%	N/A	$776K+35.4%
Investing Cash Flow	$0	$0	$0-100.0%	$0	$0	$0	$1.2M	$0
Financing Cash Flow	$40.9M+4414.7%	$27.6M+34.8%	$24.1M+29147.0%	$4.5M+1187.0%	$906K-41.2%	$20.5M+761.3%	-$83K-102.3%	$353K-93.4%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

IRD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	-271.9%	-564.7%	-55.5%-101.2pp	45.7%	-3854.8%	N/A	-139.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-349.3%	-523.4%	-52.4%-97.3pp	44.9%	-9625.3%	N/A	-205.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-323.1%+532.5pp	-855.6%-835.6pp	-20.0%-58.7pp	38.7%+293.8pp	-255.1%	N/A	N/A	N/A	-150.8%-96.3pp	-54.6%+22.1pp	-76.6%-6.9pp	-69.7%+5.6pp	-75.2%-9.9pp	-65.3%+40.7pp	-106.0%
Return on Assets	-98.7%+57.4pp	-156.1%-137.6pp	-18.5%-55.0pp	36.5%+253.9pp	-217.4%-78.2pp	-139.2%+206.6pp	-345.8%-256.2pp	-89.6%-0.1pp	-89.4%-45.2pp	-44.2%+13.8pp	-58.0%-2.8pp	-55.2%-6.7pp	-48.6%-6.8pp	-41.7%+41.1pp	-82.9%
Current Ratio	6.43+3.2x	3.24-10.1x	13.35-4.4x	17.79+11.0x	6.76+1.2x	5.55+5.4x	0.19-4.9x	5.04	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.07+0.1x	0.00-0.1x	0.080.0x	0.06-0.1x	0.17	N/A	N/A	N/A	0.69+0.5x	0.23-0.1x	0.32+0.1x	0.26-0.3x	0.550.0x	0.56+0.3x	0.28
Asset Turnover	0.280.0x	0.30-0.1x	0.35-0.5x	0.81+0.8x	0.020.0x	0.00-1.7x	1.68	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-120.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-2182.8%	-665.9%	-296.3%	-269.9%	-309.0%	-227.2%	-884.0%	-207.1%
Net Margin	-1072.6%	-3038.3%	-427.5%	-566.9%	-257.5%	-187.5%	-816.7%	-194.6%
Return on Equity	N/A	N/A	-107.7%+414.9pp	-292.5%-270.6pp	-42.5%-23.4pp	-161.5%-146.1pp	-522.5%-512.9pp	-21.9%-33.0pp
Return on Assets	-8.7%+10.5pp	-98.1%-81.1pp	-32.9%+62.4pp	-48.3%-29.7pp	-19.2%-1.9pp	-17.0%-3.3pp	-95.3%-86.4pp	-18.6%-28.9pp
Current Ratio	12.19+10.3x	7.13+5.2x	6.43+3.2x	1.23-5.4x	1.90-8.8x	1.98-7.0x	3.24-10.1x	6.63-7.2x
Debt-to-Equity	N/A	N/A	0.07+0.1x	0.180.0x	0.060.0x	8.49+8.4x	0.00-0.1x	0.18+0.1x
Asset Turnover	0.01-0.1x	0.03-0.1x	0.080.0x	0.090.0x	0.070.0x	0.09+0.1x	0.12+0.1x	0.10-0.1x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Opus Genetics, Inc. IRD	FY2025	$14.2M	-$49.6M	N/A	$381.0M	38/100
Ovid Therapeutics Inc. OVID	FY2025	$7.3M	-$17.4M	N/A	$464.8M	66/100
Immunic, Inc. IMUX	FY2025	N/A	-$97.2M	N/A	$108.6M	—
ANEBULO PHARMAC INC ANEB	FY2025	N/A	-$8.5M	N/A	$14.7M	—
OKYO Pharma Limited OKYO	FY2025	N/A	-$4.7M	N/A	$77.1M	—
Atara Biotherapeutics, Inc ATRA	FY2025	$120.8M	$32.7M	27.1%	$95.2M	63/100

Where Opus Genetics, Inc. Ranks

Frequently Asked Questions

What is Opus Genetics, Inc.'s annual revenue?

Opus Genetics, Inc. (IRD) reported $14.2M in total revenue for fiscal year 2025. This represents a 29.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Opus Genetics, Inc.'s revenue growing?

Opus Genetics, Inc. (IRD) revenue grew by 29.1% year-over-year, from $11.0M to $14.2M in fiscal year 2025.

Is Opus Genetics, Inc. profitable?

No, Opus Genetics, Inc. (IRD) reported a net income of -$49.6M in fiscal year 2025.

What is Opus Genetics, Inc.'s EBITDA?

Opus Genetics, Inc. (IRD) had EBITDA of -$38.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Opus Genetics, Inc. have?

As of fiscal year 2025, Opus Genetics, Inc. (IRD) had $45.1M in cash and equivalents against $1.1M in long-term debt.

What is Opus Genetics, Inc.'s return on equity (ROE)?

Opus Genetics, Inc. (IRD) has a return on equity of -323.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Opus Genetics, Inc.'s operating cash flow?

Opus Genetics, Inc. (IRD) recorded an outflow of $35.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Opus Genetics, Inc.'s total assets?

Opus Genetics, Inc. (IRD) had $50.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Opus Genetics, Inc. spend on research and development?

Opus Genetics, Inc. (IRD) invested $30.8M in research and development during fiscal year 2025.

How many shares does Opus Genetics, Inc. have outstanding?

Opus Genetics, Inc. (IRD) had 71M shares outstanding as of fiscal year 2025.

What is Opus Genetics, Inc.'s current ratio?

Opus Genetics, Inc. (IRD) had a current ratio of 6.43 as of fiscal year 2025, which is generally considered healthy.

What is Opus Genetics, Inc.'s debt-to-equity ratio?

Opus Genetics, Inc. (IRD) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Opus Genetics, Inc.'s return on assets (ROA)?

Opus Genetics, Inc. (IRD) had a return on assets of -98.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Opus Genetics, Inc.'s P/E ratio?

Opus Genetics, Inc. (IRD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $381.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Opus Genetics, Inc.'s price-to-sales ratio?

Opus Genetics, Inc. (IRD) trades at 38.7x sales, its market capitalization divided by revenue of $9.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $381.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Opus Genetics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Opus Genetics, Inc. (IRD) held $45.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $35.3M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Opus Genetics, Inc.'s Altman Z-Score?

Opus Genetics, Inc. (IRD) has an Altman Z-Score of 0.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Opus Genetics, Inc.'s Piotroski F-Score?

Opus Genetics, Inc. (IRD) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Opus Genetics, Inc.'s earnings high quality?

Opus Genetics, Inc. (IRD) reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Opus Genetics, Inc. cover its interest payments?

Opus Genetics, Inc. (IRD) reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Opus Genetics, Inc.?

Opus Genetics, Inc. (IRD) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.